

OriGene Technologies Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850 UNITED STATES

Phone: +1-858-888-7900 Fax: +1-858-888-7904 US-info@acris-antibodies.com

OriGene EU

BP7125

Acris Antibodies GmbH

Schillerstr. 5 32052 Herford GERMANY

Phone: +49-5221-34606-0 Fax: +49-5221-34606-11 info@acris-antibodies.com

Polyclonal Antibody to MAP2K1 pSer298 - Aff - Purified

Alternate names: MAP2K1 - mitogen-activated protein kinase kinase 1, MAPKK1, MEK1, MKK1, PRKMK1

Catalog No.: BP7125
Quantity: 0.1 ml

Background: Mitogen-activated protein kinase kinase 1 (MEK1 or MAPKK1, 43.5 kDa) is a member of a

family of tyrosine/threonine protein kinases that activate the ERK1&2/MAPK enzymes by phosphorylating both residues within the threonine - glutamic acid - tyrosine (TEY) motif in the activation loop. MEK1&2 are also activated by dual-phosphorylation, which occurs on serines 218 and 222, in the activation loop of the MEKs. Threonine 292 of MEK1 is

phosphorylated by ERK1&2, which serves as a negative feedback loop by suppressing

activation of MEK1.

Host: Rabbit

Immunogen: Chemically synthesized phosphopeptide derived from a region of human MEK1 that

contains threonine 292.

Remarks: The sequence is conserved in many species including mouse, rat, chimp,

hamster and rabbit.

Format: State: Liquid Ig fraction

Buffer System: Dulbecco's phosphate buffered saline (without Mg2+ and Ca2+), pH 7.3 (+/-0.1), 50% glycerol with 1.0 mg/mL BSA (lgG, protease free) as a carrier containing

0.05 % sodium azide as preservative.

Applications: Western blot (starting dilution 1:1000).

Positive control: NIH3T3 +/- PDGF; recombinant wild-type vs. mutant (T292A) MEK1 treated

with ERK to induce phosphorylation.

Other applications not tested. Optimal dilutions are dependent on conditions and should

be determined by the user.

Specificity: This antibody detects MEK1.

Species: Human, mouse, rat, chimp, hamster, rabbit.

Other species not tested.

Storage: Store at 2 - 8 °C up to one week or (in aliquots) at -20 °C for longer. Centrifuge vial before

opening. Avoid repeated freezing and thawing.

Shelf life: one year from despatch.

General Readings: Zhang, Y., et al. (2004) Evidence of STAT1 phosphorylation modulated by MAPKs, MEK1 and

MSK1. Carcinogen 25(7):1165-1175.

Eblen, S.T., et al. (2004) Mitogen-activated protein kinase feedback phosphorylation regulates MEK1 complex formation and activation during cellular adhesion. Mol. Cell Biol.

24(6):2308-2317.

Sharma, P., et al. (2002) Phosphorylation of MEK1 by cdk5/p35 down-regulates the mitogen-

activated protein kinase pathway. J. Biol. Chem. 277(1):528-534.

For research and in vitro use only. Not for diagnostic or therapeutic work. Material Safety Datasheets are available at www.acris-antibodies.com or on request.

Acris Antibodies is now part of the OriGene family. Learn more at www.origene.com



OG/20121030



BP7125: Polyclonal Antibody to MAP2K1 pSer298 - Aff - Purified

Lin, C.C., et al. (2002) Thrombin-stimulated cell proliferation mediated through activation of Ras/Raf/MEK/MAPK pathway in canine cultured tracheal smooth muscle cells. Cell. Signal. 14(3):265-275.

Jin, K., et al. (2002) MEK and ERK protect hypoxic cortical neurons via phosphorylation of Bad. J. Neurochem. 80(1):119-125.

Takahashi, H., et al. (2001) Expression of human cystatin A by keratinocytes is positively regulated via the Ras/MEKK1/MKK7/JNK signal transduction pathway but negatively regulated via the Ras/Raf-1/MEK1/ERK pathway. J. Biol. Chem. 276(39):36632-36638. Xu, B., et al. (1999) The N-terminal ERK-binding site of MEK1 is required for efficient feedback phosphorylation by ERK2 in vitro and ERK activation in vivo. J. Biol. Chem. 274(48):34029-34035.

Brunet, A., et al. (1994) Growth factor-stimulated MAP kinase induces rapid retrophosphorylation and inhibition of MAP kinase kinase (MEK1). FEBS Lett. 346(2-3):299-303.

Protocols: Western Blotting Procedure

- 1. Lyse approximately 10e7 cells in 0.5 mL of ice cold Cell Lysis Buffer (formulation provided below). This buffer, a modified RIPA buffer, is suitable for recovery of most proteins, including membrane receptors, cytoskeletal-associated proteins, and soluble proteins. Other cell lysis buffer formulations, such as Laemmli sample buffer and Triton-X 100 buffer, are also compatible with this procedure. Additional optimization of the cell stimulation protocol and cell lysis procedure may be required for each specific application.
- 2. Remove the cellular debris by centrifuging the lysates at $14,000 \times g$ for 10 minutes. Alternatively, lysates may be ultracentrifuged at $100,000 \times g$ for 30 minutes for greater clarification.
- 3. Carefully decant the clarified cell lysates into clean tubes and determine the protein concentration using a suitable method, such as the Bradford assay. Polypropylene tubes are recommended for storing cell lysates.
- 4. React an aliquot of the lysate with an equal volume of 2x Laemmli Sample Buffer (125 mM Tris, pH 6.8, 10% glycerol, 10% SDS, 0.006% bromophenol blue, and 130 mM dithiothreitol [DTT]) and boil the mixture for 90 seconds at 100°C.
- 5. Load 10-30 μg of the cell lysate into the wells of an appropriate single percentage or gradient minigel and resolve the proteins by SDS-PAGE.
- 6. In preparation for the Western transfer, cut a piece of PVDF membrane slightly larger than the gel. Soak the membrane in methanol for 1 minute, then rinse with ddH2O for 5 minutes. Alternatively, nitrocellulose may be used.
- 7. Soak the membrane, 2 pieces of Whatman paper, and Western apparatus sponges in transfer buffer (formulation provided below) for 2 minutes.
- 8. Assemble the gel and membrane into the sandwich apparatus.
- 9. Transfer the proteins at 140 mA for 60-90 minutes at room temperature.
- 10. Following the transfer, rinse the membrane with Tris buffered saline for 2 minutes.
- 11. Block the membrane with blocking buffer (formulation provided below) for one hour at room temperature or overnight at 4°C.
- 12. Incubate the blocked blot with primary antibody at a 1:1000 starting dilution in Tris buffered saline supplemented with 1% Ig-free BSA and 0.1% Tween 20 overnight at 4°C or for two hours at room temperature.
- 13. Wash the blot with several changes of Tris buffered saline supplemented with 0.1% Tween 20.
- 14. Detect the antibody band using an appropriate secondary antibody, such as goat F(ab)2 anti-rabbit IgG alkaline phosphatase conjugate or goat F(ab)2 anti-rabbit IgG horseradish peroxidase conjugate in conjunction with your chemiluminescence reagents and instrumentation.





Cell Lysis Buffer Formulation: 10 mM Tris, pH 7.4 100 mM NaCl 1 mM EDTA 1 mM EGTA 1 mM NaF 20 mM Na4P2O7 2 mM Na3VO4 0.1% SDS 0.5% sodium deoxycholate 1% Triton-X 100 10% glycerol 1 mM PMSF (made from a 0.3 M stock in DMSO) or 1 mM AEBSF (water soluble version of PMSF) 60 μg/mL aprotinin 10 μg/mL leupeptin 1 µg/mL pepstatin (alternatively, protease inhibitor cocktail such as Sigma Cat. # P2714 may be used)

Transfer Buffer Formulation:
2.4 gm Tris base
14.2 gm glycine
200 mL methanol
Q.S. to 1 liter, then add 1 mL 10% SDS.
Cool to 4°C prior to use.

Tris Buffered Saline Formulation: 20 mM Tris-HCl, pH 7.4 0.9% NaCl

Blocking Buffer Formulation: 100 mL Tris buffered saline 5 gm BSA 0.1 mL Tween 20

Peptide Competition Experiment

The specificity of a Phosphorylation Site Specific Antibody (PSSA) in each experimental system can be confirmed through peptide competition. In this technique, aliquots of antibody are pre-incubated with peptide containing the sequence of the phosphopeptide immunogen used to raise the PSSA and the corresponding non-phosphopeptide. Following preincubation with the peptide, each antibody preparation is then used as a probe in antibody-based detection methods, such as Western blotting, immunocytochemistry, flow cytometry, or ELISA. With a PSSA specific for the phosphorylated target protein, pre-incubation with an excess of peptide containing the sequence of the phosphopeptide immunogen will block all antigen binding sites, while pre-incubation with the corresponding non-phosphopeptide will not affect the antibody.

In performing the Peptide Competition Experiment, it is important to note that the optimal dilutions of both antibody and peptide should be determined empirically for each specific application. The optimal dilution of antibody in these procedures is below saturating, as determined by previous experiments in your system.





BP7125: Polyclonal Antibody to MAP2K1 pSer298 - Aff - Purified

The optimal dilution of peptide used in these procedures will depend on the overall affinity or avidity of the antibody, as well as the quantity of the target antigen. A 50-150 fold molar excess of peptide to antibody is found to be effective for most peptide competition experiments.

In the example presented below, the PSSA is used as a dilution of 1:1000 and the peptides are used at a concentration of 333 nM. The total volume of the phosphopeptide and nonphosphopeptide pre-incubated antibody preparations is 2 mL, sufficient for probing Western blot strips, as well as for use in other antibody-based detection methods. Under these conditions, the molar excess of peptide to antibody is \rangle / = 50.

Procedure:

- 1. Prepare three identical test samples, such as identical PVDF or nitrocellulose strips to which the protein of interest has been transferred. The test samples should be blocked using a blocking buffer, such as Tris buffered saline supplemented with 0.1% Tween 20, and either 5% BSA or 5% non-fat dried milk.
- 2. Prepare 6.5 mL of working antibody stock solution (1:1000 in this example) by adding 6.5 μ L of antibody stock solution to 6.5 mL of buffer containing blocking protein, such as TBS supplemented with 0.1% Tween 20, and either 3% BSA or 3% non-fat dried milk.
- 3. Apportion the unused PSSA into working aliquots and store at -20°C for future use (the stock PSSA contains 50% glycerol and will not freeze at this temperature).
- 4. Allow the lyophilized control peptides to reach room temperature, ideally under desiccation. 5. Reconstitute each of the control peptides to a concentration of 66.7 μ M with nanopure water. (i.e. for a peptide with a molecular mass of 1500, reconstitution with 1 mL water yields a solution with a concentration of 66.7 μ M).
- 6. Apportion the unused reconstituted peptide solutions into working aliquots and store at -20°C for future use.
- 7. Label 3 test tubes as follows:
- tube 1: water only no peptide control
- tube 2: phosphopeptide
- tube 3: non-phosphopeptide
- 8. Into each tube, pipette the following components
- tube 1: 2 mL diluted PSSA solution plus 10 μL nanopure water
- tube 2: 2 mL diluted PSSA solution plus 10 µL phosphopeptide
- tube 3: 2 mL diluted PSSA solution plus 10 μL non-phosphopeptide
- 9. Incubate the three tubes for 30 minutes at room temperature with gentle rocking. During this incubation, the peptides have the chance to bind to the combining site of the antibody.
- 10. At the end of the incubation step, transfer the contents of each of the three tubes to clean reaction vessels containing one of the three identical test samples.

For Western blotting strips:

Incubate the strips with the pre-incubated antibody preparations for 1 hour at room temperature or overnight at 4°C.

Wash each strip four times, five minutes each, to remove unbound antibody. Transfer each strip to a new solution containing a labeled secondary antibody [e.g., goat F(ab)2 antirabbit IgG alkaline phosphatase conjugate or goat F(ab)2 anti-rabbit IgG horseradish peroxidase conjugate.

Remove unbound secondary antibody by thorough washing, and develop the signal using your chemiluminescent reagents and instrumentation.

The signal obtained with antibody incubated with the "Water Only, No Peptide Control" (Tube 1), represents the maximum signal in the assay. This signal should be eliminated by preincubation with the "Phosphopeptide" (Tube 2), while pre-incubation with the "Non-Phosphopeptide" (Tube 3) should not impact the signal. If the "Phosphopeptide" only partially eliminates the signal, repeat the procedure using twice the volume of water or





peptide solutions listed in Step 8. If partial competition is seen following pre-incubation with the "Non-Phosphopeptide", repeat the procedure using half the volumes of water or peptide solutions listed in Step 8.

Pictures:

Peptide Competition Extracts of NIH3T3 cells untreated (lane 1) or treated with 50 ng/mL PDGF for 15 minutes (lanes 2-5) were resolved by SDS-PAGE on a 10% Trisglycine gel and transferred to PVDF. The membrane was blocked with a 4% BSA-TBST buffer for one hour at room temperature, then incubated with the MEK1 [pT292] antibody in a 1% BSA-TBST buffer for two hours at room temperature, following prior incubation with: no peptide (1, 2), a generic phosphothreonine-containing peptide (3), the non-phosphopeptide corresponding to the phosphopeptide immunogen (4), or the phosphopeptide immunogen (5). After washing, the membrane was incubated with goat F(ab')2 anti-rabbit IgG HRP conjugate and signals were detected using the Pierce SuperSignalTM method. The data show that only the phosphopeptide corresponding to MEK1 [pT292] blocks the antibody signal, demonstrating the specificity of the antibody. The data also show the induction of MEK1 [pT292] phosphorylation by the addition of PDGF to this cell system. In addition, this antibody did not recognize a recombinant MEK1 T292A mutant protein (kindly provided by Dr. Natalie Ahn, University of Colorado), further demonstrating its specificity for MEK1 [pT292] (data not shown).

